Receptor-type tyrosine-protein phosphatase N (IA-2)

Receptor-type tyrosine-protein phosphatase N (IA-2), also referred to as Islet Antigen 2, is a major transmembrane protein primarily located in the membrane of dense-core secretory granules within pancreatic beta cells and various neuroendocrine tissues [1][2]. Although it is structurally classified as a member of the protein tyrosine phosphatase (PTP) family, IA-2 lacks significant catalytic activity and instead functions as a critical regulator of insulin secretion and the maintenance of secretory granule pools [1]. IA-2 is most clinically significant as a primary autoantigen in the pathogenesis of Type 1 Diabetes Mellitus (T1DM). Autoantibodies directed against IA-2 (IA-2A) serve as essential biomarkers for the prediction and diagnosis of T1DM, often detectable in the serum of individuals months or years before clinical symptoms manifest [3][4]. While there are currently no drugs that directly inhibit the IA-2 protein, therapeutic efforts focus on immunomodulatory agents like Teplizumab, which are designed to arrest the T-cell-mediated destruction of IA-2-containing beta cells to preserve endogenous insulin production [5]. Consequently, IA-2 remains a focal point for both diagnostic assay development and the advancement of antigen-specific immunotherapies aimed at disease modification in early-stage T1DM [2][4].

Other names

Islet antigen-related tyrosine phosphatase 2PTPRNIslet antigen 2Islet cell antigen 512ICA512Islet-cell autoantigen 3IA-2 autoantigen

Prevention of autoimmune destruction of IA-2-expressing pancreatic beta cells through T-cell modulation or the induction of antigen-specific immune tolerance.